For most of her life, Oakwood Village resident Annyanna Cash was in and out of hospitals, her schedule dictated by sickle cell pain crises instead of any kind of normal routine. After enrolling in a Cleveland Clinic clinical trial, she told local TV that life looks very different. Since receiving an experimental sickle cell treatment, Cash says she is now going months at a time without the crippling pain that once defined her days. The move from frequent emergency room visits to talking about work, family and routine doctor appointments has left her and her relatives cautiously hopeful.
How the treatment works
The therapy, called reni‑cel (formerly EDIT‑301), is an investigational, one‑time gene‑editing cell treatment that uses a patient’s own blood‑forming stem cells. The cells are modified so they produce protective fetal hemoglobin, which is intended to cut down on the red blood cell sickling that drives pain episodes and organ damage. According to Cleveland Clinic, the process involves collecting stem cells, performing CRISPR‑style editing outside the body, using chemotherapy to clear space in the bone marrow, then reinfusing the edited cells.
Local patient speaks
As reported by FOX 8 Cleveland, Cash spent most of her life getting care in hospitals before undergoing the procedure. Since treatment, she and her family have noticed a drop in pain crises and an increase in ordinary, uneventful days, something that was rare before the trial.
What the early data show
Early numbers from the multicenter RUBY trial have grabbed attention. Editas Medicine reported that, as of a late‑2024 data cutoff, 27 of 28 people treated with reni‑cel were free of vaso‑occlusive events, the painful blockages in blood vessels that send many sickle cell patients to the hospital. Mean hemoglobin levels rose from about 9.8 g/dL at the start of treatment to roughly 13.8 g/dL by month six. In its update, Editas Medicine also reported rapid, sustained increases in fetal hemoglobin and gains on pain and quality‑of‑life measures. Investigators cautioned that reni‑cel still involves the same serious risks that come with myeloablative conditioning and transplant‑level care.
Access, caution and next steps
For now, reni‑cel is still considered investigational and is only available through clinical trials, not as an approved treatment. The pathway is intensive, involving months of evaluation, chemotherapy to clear the bone marrow and careful monitoring afterward. Cleveland Clinic and Editas investigators say they need more time, more participants and longer follow‑up to know how durable and safe the results will be over the long haul. For a broader national view on where gene therapy stands, Time and other outlets note that two gene therapies for sickle cell received FDA approval in late 2023, a milestone that reshaped the treatment landscape while leaving big questions about access and cost.
For Cash and other local patients taking part in clinical trials at Cleveland Clinic, the impact is both practical and emotional: fewer hospital stays, fewer missed days of work and more room to think about the future. As FOX 8 Cleveland reports, she is already making plans she never thought were in reach before the trial, even as her physicians urge patience while researchers continue to collect longer‑term data.
